» Articles » PMID: 33649827

Molecular Features and Gene Expression Signature of Metastatic Colorectal Cancer (Review)

Overview
Journal Oncol Rep
Specialty Oncology
Date 2021 Mar 2
PMID 33649827
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Uncontrollable metastatic outgrowth process is the leading cause of mortality worldwide, even in the case of colorectal cancer. Colorectal cancer (CRC) accounts for approximately 10% of all annually diagnosed cancers and 50% of CRC patients will develop metastases in the course of disease. Most patients with metastatic CRC have incurable disease. Even if patients undergo resection of liver metastases, the 5‑year survival rate ranges from 25 to 58%. Next‑generation sequencing of tumour specimens from large colorectal cancer patient cohorts has led to major advances in elucidating the genomic landscape of these tumours and paired metastases. The expression profiles of primary CRC and their metastatic lesions at both the gene and pathway levels were compared and led to the selection of early driver genes responsible for carcinogenesis and metastasis‑specific genes that increased the metastatic process. The genetic, transcriptional and epigenetic alteration encoded by these genes and their combination influence many pivotal signalling pathways, enabling the dissemination and outgrowth in distant organs. Therapeutic regimens affecting several different active pathways may have important implications for therapeutic efficacy.

Citing Articles

The impact of apoptosis-inducing MAPK and glycolytic pathways modulated by Aloe vera and royal jelly in lung and colorectal cancer.

Koprulu T, Gezer B, Erkal Cam B Med Oncol. 2025; 42(2):51.

PMID: 39838121 PMC: 11750912. DOI: 10.1007/s12032-025-02606-7.


miR-4486 inhibits colorectal cancer proliferation via targeting MAP2K4 to inhibit the activation of the p38MAPK/JNK signaling.

Wang W, Chen L, Xu F, Chen R, Li Q, Zou L Heliyon. 2024; 10(21):e38926.

PMID: 39512455 PMC: 11539255. DOI: 10.1016/j.heliyon.2024.e38926.


Silencing GDI2 inhibits proliferation, migration and invasion of colorectal cancer through activation of p53 signaling pathway.

Ou W, Tan R, Zhai J, Sun L, Xu F, Huang X Heliyon. 2024; 10(18):e37770.

PMID: 39323841 PMC: 11422032. DOI: 10.1016/j.heliyon.2024.e37770.


Single-cell exome sequencing reveals polyclonal seeding and TRPS1 mutations in colon cancer metastasis.

Cai J, Zhang W, Lu Y, Liu W, Zhou H, Liu M Signal Transduct Target Ther. 2024; 9(1):247.

PMID: 39307879 PMC: 11417107. DOI: 10.1038/s41392-024-01960-8.


Inhibiting S-palmitoylation arrests metastasis by relocating Rap2b from plasma membrane in colorectal cancer.

Zhu J, Cao X, Chen Z, Lai B, Xi L, Zhang J Cell Death Dis. 2024; 15(9):675.

PMID: 39277583 PMC: 11401852. DOI: 10.1038/s41419-024-07061-2.


References
1.
Zentner G, Henikoff S . Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol. 2013; 20(3):259-66. DOI: 10.1038/nsmb.2470. View

2.
Holch J, Ricard I, Stintzing S, Modest D, Heinemann V . The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2016; 70:87-98. DOI: 10.1016/j.ejca.2016.10.007. View

3.
Liu J, Wang D, Zhang C, Zhang Z, Chen X, Lian J . Identification of liver metastasis-associated genes in human colon carcinoma by mRNA profiling. Chin J Cancer Res. 2019; 30(6):633-646. PMC: 6328509. DOI: 10.21147/j.issn.1000-9604.2018.06.08. View

4.
Trinh A, Ladrach C, Dawson H, Ten Hoorn S, Kuppen P, Reimers M . Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. Br J Cancer. 2018; 119(10):1244-1251. PMC: 6251036. DOI: 10.1038/s41416-018-0230-7. View

5.
Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View